Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-Current Deffered Revenue (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $501000.0 as the latest value for Q1 2025.

  • Quarterly Non-Current Deffered Revenue fell 89.47% to $501000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $501000.0 through Mar 2025, down 89.47% year-over-year, with the annual reading at $1.2 million for FY2024, 77.84% down from the prior year.
  • Non-Current Deffered Revenue for Q1 2025 was $501000.0 at TScan Therapeutics, down from $1.2 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $7.8 million in Q3 2023, with the low at $501000.0 in Q1 2025.
  • Average Non-Current Deffered Revenue over 4 years is $4.0 million, with a median of $4.0 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 48.26% in 2024, then plummeted 89.47% in 2025.
  • Over 4 years, Non-Current Deffered Revenue stood at $1.5 million in 2021, then surged by 275.55% to $5.6 million in 2023, then plummeted by 77.84% to $1.2 million in 2024, then tumbled by 59.79% to $501000.0 in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $501000.0, $1.2 million, and $3.7 million for Q1 2025, Q4 2024, and Q3 2024 respectively.